0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innovation Pharmaceuticals
Its shares trade under the ticker IPIX. It has been listed since 2 April 2007. In the fiscal year to 30 June 2023, it reported revenue of $18,000 and a net loss of $3.2m. At that date it held total assets of $7.5m and shareholders' equity of $2.0m.
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with oncology, dermatology and antimicrobial applications. The firm owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics. The firm's clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Prurisol for the treatment of psoriasis, and Brilacidin for treatments of skin infections, prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis. The firm focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics and inflammatory disease.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Apr 2007
- Employees
- 4
- Website
- ipharminc.com ↗
Leadership
Pay as last reported
- Mr. Leo EhrlichChairman of the Board, Chief Executive Officer, Chief Financial Officer$565,850
- Ms. Jane HarnessSenior Vice President - Clinical Sciences and Portfolio Management$275,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovation Pharmaceuticals Inc has a strong intellectual property portfolio, including patents and trademarks, which provides a competitive advantage in the pharmaceutical industry.
- The company's research and development capabilities are advanced, allowing for the discovery and development of innovative drugs.
- Innovation Pharmaceuticals Inc has a dedicated team of highly skilled scientists and researchers who have expertise in various therapeutic areas.
Weaknesses
- The company is heavily dependent on external funding sources for its research and development activities, which may pose financial risks and limitations.
- Innovation Pharmaceuticals Inc currently has a limited product pipeline, with only a few drug candidates in various stages of development.
- The company's market penetration is relatively low, limiting its ability to generate significant revenues and market share.
Opportunities
- The increasing demand for novel and effective drugs in the pharmaceutical market provides an opportunity for Innovation Pharmaceuticals Inc to capture market share with its innovative drug candidates.
- The company can explore potential collaborations and partnerships with pharmaceutical giants to leverage their resources and distribution networks for commercializing its products.
- Expansion into emerging markets and the exploration of untapped therapeutic areas could provide new growth opportunities for the company.
Threats
- Intense competition from established pharmaceutical companies and generic drug manufacturers poses a threat to Innovation Pharmaceuticals Inc's market position and profitability.
- Regulatory approvals and compliance requirements can be time-consuming and expensive, potentially delaying the commercialization of the company's drug candidates.
- Economic downturns and changes in healthcare policies could affect market demand for pharmaceutical products and potentially impact the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.